Sign in Subscribe
Nanotechnology

Breakthrough in Cancer Treatment: Targeted Contrast Agent for MRI Detection of Tumor-Infiltrating Lymphocytes

Strategic Insights

— 1 min read

Researchers at the Tehran University of Medical Sciences have made a significant discovery in the field of cancer treatment. Using magnetic resonance imaging (MRI) and targeted contrast agents, they have demonstrated the ability to detect tumor-infiltrating lymphocytes (TILs), a key indicator of cancer treatment effectiveness. The breakthrough involves the development of a novel contrast agent based on dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs-DEX) that targets CD3+ lymphocytes.

Key Takeaways:

  • The research aimed to investigate the feasibility of using a targeted contrast agent for MRI detection of TILs in cancer patients.
  • The team synthesized an MRI contrast agent by conjugating SPIONs-DEX to an anti-CD3 monoclonal antibody via cyanogen bromide as a cross-linker.
  • In vitro assessments showed that the developed contrast agent had a higher labeling efficiency for CD3+ lymphocytes compared to SPIONs-DEX alone.
  • In vivo MRI of a xenograft model of CD3+ lymphocytes revealed significant signal loss after intravenous injection of the bioconjugate.
  • The histopathological evaluation of xenograft tumors confirmed the labeling of lymphocytes by the targeted contrast agent.
  • This approach could open up new horizons in non-invasive assessment of TILs to identify patients eligible for immunotherapy.
  • Mohammad Ali Oghabian and his team have made significant contributions to this research, including the development of the targeted contrast agent and in vitro and in vivo assessments.

Statistics:

  • The research demonstrated a 34% and 21% signal loss in T*-weighted and T-weighted images, respectively, after intravenous injection of the bioconjugate.
  • The labeling efficiency of the developed contrast agent for CD3+ lymphocytes was higher by 30% compared to SPIONs-DEX alone.
  • In vivo MRI studies were conducted using a xenograft model of CD3+ lymphocytes.
  • The research has been peer-reviewed and published in ChemMedChem, a journal by Wiley-VCH Verlag GmbH.

Sources:

  • "Magnetic Resonance Imaging of Tumor-Infiltrating Lymphocytes by Anti-CD3-Conjugated Iron Oxide Nanoparticles." ChemMedChem, 2022.
  • NewsRx LLC. "Tehran University of Medical Sciences Reports Findings in Nanoparticles (Magnetic Resonance Imaging of Tumor-Infiltrating Lymphocytes by Anti-CD3-Conjugated Iron Oxide Nanoparticles)." Nanotechnology Weekly. April 18, 2022; p 1677.

Read more